A Phase 1 interventional study of alendronate sodium (+) cholecalciferol and Comparator: alendronate in Osteoporosis, sponsored by Organon and Co. Completed. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-02-08.
Sponsored by Organon and Co · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies testing alendronate in Osteoporosis — 2 open to participants now, 4 under way, none of them phase 3. Alendronate · Osteoporosis.
Among the 51 studies testing alendronate in Osteoporosis, this one is the 8th largest by enrollment, is one of 5 that started in 2003, is one of 2 in phase 1, and was the 28th registered.
1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.
Browse Osteoporosis studies →2 of the 51 studies testing alendronate in Osteoporosis are open now, in 2 countries. Recruiting first, the newest first:
Odense University Hospital · Sites in Denmark
Women only
Paul F Netzel · Sites in United States
Ages 45+ · Women only
By country, each count listing its studies:
Alendronate: first FDA approval 1995 (FOSAMAX), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →
Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 16 · Phase 3 15 · Phase 4 17
First in 1997; this study’s year is marked. 5 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 244 is above the median of 88 across 1,084 interventional studies indexed under Osteoporosis.
Median enrollment 60 across the 51 interventional studies. Of the 42 that completed or were terminated, 18 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 51 have an industry lead sponsor. The 10 most frequent:
This study is registered under Organon and Co, one of the names counted as Organon & Co.. Under that name alone:
Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
10 studies in Osteoporosis by Organon & Co.: none open now, none under way, none of them phase 3. Of 10 finished, 5 (50%) have results posted.
Among the 10 studies in Osteoporosis by Organon & Co., this one is one of 2 that started in 2003, is one of 3 in phase 1, and was the 8th registered.
Organon & Co.’s Osteoporosis studies by the year they started, since 2001.
1 of the studies testing alendronate in Osteoporosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05151484Madhumathi RaoNovel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover | 2027-01-31 |
Add it to your calendar (.ics) → With an account.
Among the 51 studies testing alendronate in Osteoporosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Organon & Co.’s 10 in Osteoporosis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the bioequivalence of alendronate in combination with vitamin D (cholecalciferol) compared to alendronate alone and the bioequivalence of vitamin D in combination with alendronate compared to vitamin D alone.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
alendronate/vitamin D combination then alendronate
Drug: alendronate sodium (+) cholecalciferol · Drug: Comparator: alendronate
alendronate then alendronate/vitamin D combination
Drug: alendronate sodium (+) cholecalciferol · Drug: Comparator: alendronate
alendronate/vitamin D combination then vitamin D
Drug: alendronate sodium (+) cholecalciferol · Dietary Supplement: Comparator: cholecalciferol (Vitamin D)
vitamin D then alendronate/vitamin D combination
Drug: alendronate sodium (+) cholecalciferol · Dietary Supplement: Comparator: cholecalciferol (Vitamin D)
A single dose tablet of 70 mg alendronate/2800 IU (international unit) vitamin D in one treatment period of each sequence. There will be a 12 day interval between each treatment period.
A single dose table of 70 mg alendronate in one treatment period of each sequence. There will be a 12 day interval between each treatment period.
A single dose tablet of 2800 IU vitamin D in one treatment period of each sequence. There will be a 12 day interval between each treatment period.
Part 1: The Total Urinary Excretion of Alendronate With Alendronate/Vitamin D Combination Tablet Relative to Alendronate Tablet
Urinary excretion of alendronate was determined over a 36-hour period following single-dose administration of a 70 mg alendronate/2800-IU vitamin D3 combination tablet or 70 mg alendronate alone tablet. Urine for each treatment period was collected at -2 to 0 hours predose, 0 to 8, 8 to 24, and 24 to 36 hours postdose.
Time frame: On Day 1 across the 36-hour urinary collection period (Periods 1 and 2).
Part II : The Pharmacokinetic Parameters AUC0-120 hr of Vitamin D in Combination Tablet Relative to Vitamin D Tablet
Serum vitamin D3 pharmacokinetic parameter AUC0-120 hr (area under the serum concentration-time curve) after treatment on Day 1was calculated following single-dose administration of a 70 mg alendronate/2800-IU vitamin D3 combination tablet or 2800-IU vitamin D3 tablet. Serum for each treatment period was collected at -24, -18, -12, -6, and 0 hours predose, and 2, 3, 5, 7, 9, 12, 16, 24, 36, 48, 72, 96, and 120 hours postdose.
Time frame: On Day 1 across the 120-hour plasma collection period (Periods 1 and 2).
Part II : The Pharmacokinetic Parameters Cmax of Vitamin D in Combination Tablet Relative to Vitamin D Tablet
Serum vitamin D3 pharmacokinetic parameter Cmax (maximum concentration observed in serum) after treatmen on Day 1was calculated following single-dose administration of a 70 mg alendronate/2800-IU vitamin D3 combination tablet or 2800-IU vitamin D3 tablet. Serum for each treatment period was collected at -24, -18, -12, -6, and 0 hours predose, and 2, 3, 5, 7, 9, 12, 16, 24, 36, 48, 72, 96, and 120 hours postdose.
Time frame: On Day 1 across the 120-hour plasma collection period (Periods 1 and 2).
Participants were recruited from the following clinical research organizations: Thomas Jefferson University, Division of Clinical Pharmacology, Philadelphia, PA; Clinical Pharmacology Associates, Miami, FL; and Northwest Kinetics, Tacoma, WA, between May 2003 and July 2003.
| Milestone | Alendronate/Vitamin D Combination Then Alendronate | Alendronate Then Alendronate/Vitamin D Combination | Alendronate/Vitamin D Combination Then Vitamin D | Vitamin D Then Alendronate/Vitamin D Combination |
|---|---|---|---|---|
| Started | 107 | 107 | 0 | 0 |
| Completed | 104 | 103 | 0 | 0 |
| Not completed | 3 | 4 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 3 | 1 | 0 | 0 |
| Milestone | Alendronate/Vitamin D Combination Then Alendronate | Alendronate Then Alendronate/Vitamin D Combination | Alendronate/Vitamin D Combination Then Vitamin D | Vitamin D Then Alendronate/Vitamin D Combination |
|---|---|---|---|---|
| Started | 104 | 103 | 0 | 0 |
| Completed | 104 | 103 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Alendronate/Vitamin D Combination Then Alendronate | Alendronate Then Alendronate/Vitamin D Combination | Alendronate/Vitamin D Combination Then Vitamin D | Vitamin D Then Alendronate/Vitamin D Combination |
|---|---|---|---|---|
| Started | 0 | 0 | 14 | 16 |
| Completed | 0 | 0 | 14 | 14 |
| Not completed | 0 | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 2 |
| Milestone | Alendronate/Vitamin D Combination Then Alendronate | Alendronate Then Alendronate/Vitamin D Combination | Alendronate/Vitamin D Combination Then Vitamin D | Vitamin D Then Alendronate/Vitamin D Combination |
|---|---|---|---|---|
| Started | 0 | 0 | 14 | 14 |
| Completed | 0 | 0 | 14 | 14 |
| Not completed | 0 | 0 | 0 | 0 |
Urinary excretion of alendronate was determined over a 36-hour period following single-dose administration of a 70 mg alendronate/2800-IU vitamin D3 combination tablet or 70 mg alendronate alone tablet. Urine for each treatment period was collected at -2 to 0 hours predose, 0 to 8, 8 to 24, and 24 to 36 hours postdose.
| micrograms (μg) | Alendronate/Vitamin D Combination | Alendronate |
|---|---|---|
| Part 1: The Total Urinary Excretion of Alendronate With Alendronate/Vitamin D Combination Tablet Relative to Alendronate Tablet | 197.5 ± 329.1 | 191.9 ± 522.2 |
Serum vitamin D3 pharmacokinetic parameter AUC0-120 hr (area under the serum concentration-time curve) after treatment on Day 1was calculated following single-dose administration of a 70 mg alendronate/2800-IU vitamin D3 combination tablet or 2800-IU vitamin D3 tablet. Serum for each treatment period was collected at -24, -18, -12, -6, and 0 hours predose, and 2, 3, 5, 7, 9, 12, 16, 24, 36, 48, 72, 96, and 120 hours postdose.
| ng*hr/mL | Alendronate/Vitamin D Combination | Vitamin D |
|---|---|---|
| Part II : The Pharmacokinetic Parameters AUC0-120 hr of Vitamin D in Combination Tablet Relative to Vitamin D Tablet | 296.4 ± 375.5 | 337.9 ± 344.2 |
Serum vitamin D3 pharmacokinetic parameter Cmax (maximum concentration observed in serum) after treatmen on Day 1was calculated following single-dose administration of a 70 mg alendronate/2800-IU vitamin D3 combination tablet or 2800-IU vitamin D3 tablet. Serum for each treatment period was collected at -24, -18, -12, -6, and 0 hours predose, and 2, 3, 5, 7, 9, 12, 16, 24, 36, 48, 72, 96, and 120 hours postdose.
| ng/mL | Alendronate/Vitamin D Combination | Vitamin D |
|---|---|---|
| Part II : The Pharmacokinetic Parameters Cmax of Vitamin D in Combination Tablet Relative to Vitamin D Tablet | 5.9 ± 3.3 | 6.6 ± 3.1 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Alendronate/Vitamin D Combination | — | 0/240 (0%) | 55/240 (22.9%) |
| Alendronate | — | 0/214 (0%) | 39/214 (18.2%) |
| Vitamin D | — | 0/30 (0%) | 9/30 (30%) |
| Event | Alendronate/Vitamin D Combination | Alendronate | Vitamin D |
|---|---|---|---|
| HeadacheNervous system disorders | 30/240 | 20/214 | 3/30 |
| DiarrhoeaGastrointestinal disorders | 9/240 | 6/214 | 1/30 |
| ConjunctivitisEye disorders | 1/240 | 0/214 | 1/30 |
| NauseaGastrointestinal disorders | 4/240 | 4/214 | 1/30 |
| InjuryInjury, poisoning and procedural complications | 0/240 | 0/214 | 1/30 |
| Haemoglobin DecreasedInvestigations | 1/240 | 0/214 | 1/30 |
| White Blood Cells Urine PositiveInvestigations | 0/240 | 0/214 | 1/30 |
| Muscle CrampMusculoskeletal and connective tissue disorders | 0/240 | 0/214 | 1/30 |
| VomitingGastrointestinal disorders | 5/240 | 3/214 | 0/30 |
| DyspepsiaGastrointestinal disorders | 3/240 | 4/214 | 0/30 |
| Age, Continuous(years) | Part I | Part II | Total |
|---|---|---|---|
| Mean | 41.6 (18 to 65) | 35.2 (19 to 54) | 40.8 (18 to 65) |
| Sex: Female, Male(Participants) | Part I | Part II | Total |
|---|---|---|---|
| Female | 119 | 14 | 133 |
| Male | 95 | 16 | 111 |
| Height(Centimeters) | Part I | Part II | Total |
|---|---|---|---|
| Mean | 167.2 (144.8 to 190.5) | 170.4 (156.2 to 190.5) | 167.5 (144.8 to 190.5) |
| Weight(Kilograms) | Part I | Part II | Total |
|---|---|---|---|
| Mean | 72.8 (48.0 to 105.4) | 71.2 (49.9 to 98.4) | 72.6 (48.0 to 105.4) |
No study locations are listed for this record.
The record gives a start of May 2003, a primary completion of Aug 2003 and a completion of Jan 2004. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2010, 6 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Alendronate · Cholecalciferol